• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Zhejiang treats and cures the H7N9 bird flu patient with the artificial liver and in-vitro membrane lung system

tetano

Editor, Senior Moderator
machine translation

Zhejiang's first artificial liver and extracorporeal membrane oxygenation treatment of H7N9 bird flu
April 18, 2013 18:57:45

On the 18th, the Zhejiang University Medical school attached first hospital (hereafter refers to as \"Zhejiang one\") Holds the press conference to notify at present in the situation of H7N9 bird flu virus infected person this institute received a medical examination, at the meeting, Academician of the Chinese Academy of Engineering, Infectious disease diagnosis national key laboratory director Li Lanjuan said that H7N9 bird flu virus infected person who a Zhejiang first use artificial liver and in-vitro membrane lung carries on the treatment systematically, Yesterday after being removed this system, still may maintain very good oxygen and function, this indicates that the first-aid measures of hospital to H7N9 seriously injured sickness will welcome a new start. According to Zhejiang Health department, up to now, Zhejiang discovery person infects the confirmed case 25 cases of H7N9 bird flu, 2 cases of deaths. On the afternoon of 18th, Academician of the Chinese Academy of Engineering, Infectious disease diagnosis national key laboratory director Li Lanjuan has notified to the media in the situation of H7N9 bird flu virus infected person this institute accepts the treatment. As the population of bird flu infected person increases progressively, the research and development and foundation of related medicine method also become the focal point of people and media care. Li Lanjuan said that yesterday, H7N9 bird flu virus who a Zhejiang first utilization artificial liver and in-vitro membrane lung rescues systematically after removing \"artificial liver system\" and \"artificial lung system\", Still may maintain very good oxygen and function.

The Li Lanjuan, artificial liver and extracorporeal membrane oxygenation system for some explosive, as early as the mid-severe hepatitis or liver failure patients there was a clear treatment effect of the technology will be the chances of death due to severe pneumonia, according to hospital statistics from 80 % to 20%.

"This transferred to Zhejiang H7N9 avian influenza infection in oncoming condition are more ferocious, most of the patients admitted to hospital already critically ill." Said Li Lanjuan., Most of the H7N9 bird flu lungs rapidly into the "white lung" state, The poor exchange function of the lung, followed by respiratory failure.

According to Li Lanjuan, the first time the name using the artificial liver system "and" artificial lung system for the treatment of bird flu Jo only 38 years old on April 13, he was diagnosed with the H7N9 avian influenza virus infection and was transferred into Zhejiang treatment.

"The Cao Mougang turn into the Zhejiang temporary situation is very dangerous, lungs and respiratory function of the patient has a serious failure phenomenon, doctors say the patient is definitely not saved." The Li Lanjuan recalls, but she felt this patients still young, only 38 years old, there should be possible for treatment.

The Li Lanjuan, 5 days ago hospitals Jo "artificial liver technology combined" artificial lung technical "can only be maintained for treatment of the patient's life. After treatment, the patient's oxygen index in stable condition, each index is gradually stable.

To Li Lanjuan, although the patients should continue to use the ventilator to sustain life, the use of "artificial liver" technology so that the patients are temporarily converted to fire hazard, which indicates that H7N9 rescue of critically ill patients will have a new means of to start. (BEIJING, Hangzhou, April 18 / Reporter Shao Yanfei intern Shauna)


http://news.xinhuanet.com/2013-04/18/c_115444620.htm
 
Last edited by a moderator:
Re: Zhejiang treats and cures the H7N9 bird flu patient with the artificial liver and in-vitro membrane lung system

This looks to be important. I wish it was published in more languages.
 
Re: Zhejiang treats and cures the H7N9 bird flu patient with the artificial liver and in-vitro membrane lung system

This looks to be important. I wish it was published in more languages.

I hope they aren't using the pig-cells based Platform earlier tested for this liver impairment treatment....
 
Re: Zhejiang treats and cures the H7N9 bird flu patient with the artificial liver and in-vitro membrane lung system

Source: PubMed: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597613/

PLoS One. 2013; 8(3): e58738. - Published online 2013 March 14. doi: 10.1371/journal.pone.0058738 - PMCID: PMC3597613


Artificial Liver Support System Combined with Liver Transplantation in the Treatment of Patients with Acute-on-Chronic Liver Failure

Xiao Xu,1 Xiaoli Liu,2 Qi Ling,1 Qiang Wei,1 Zhikun Liu,1 Xiaowei Xu,2 Lin Zhou,1 Min Zhang,1 Jian Wu,1 Jianrong Huang,2 Jifang Sheng,2 Shusen Zheng,1,* and Lanjuan Li2,*


Abstract.

Background

The search for a strategy to provide temporary liver support and salvage the patients with acute-on-chronic liver failure (ACLF) remains an important issue. This study was designed to evaluate the experience in artificial liver support system (ALSS) combined with liver transplantation (LT) in the treatment of ACLF.


Methodology/Principal Findings

One hundred and seventy one patients with HBV related ACLF undergoing LT between January 2001 and December 2009 were included. Of the 171 patients, 115 received 247 sessions of plasma exchange-centered ALSS treatment prior to LT (ALSS-LT group) and the other 56 received emergency LT (LT group). The MELD score were 31?6 and 30?7 in ALSS-LT group and LT group. ALSS treatment resulted in improvement of liver function and better tolerance to LT. The average level of serum total bilirubin before LT was lower than that before the first time of ALSS treatment. The median waiting time for a donor liver was 12 days (2?226 days) from the first run of ALSS treatment to LT. Compared to LT group, the beneficial influences of ALSS on intraoperative blood loss and endotracheal intubation time were also observed in ALSS-LT group. The 1-year and 5-year survival rates in the ALSS-LT group and LT group were 79.2% and 83%, 69.7% and 78.6%.


Conclusions/Significance

Plasma exchange-centered ALSS is beneficial in salvaging patients with ACLF when a donor liver is not available. The consequential LT is the fundamental treatment modality to rescue these patients and lead to a similar survival rate as those patients receiving emergency transplantation.



-
------
 
Back
Top Bottom